Phreesia Shares Plunge 27% Following Revenue Guidance Cut
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: PRnewswire
- Stock Plunge: Phreesia's corrective disclosure on March 30, 2026, led to a 27% drop in share price, losing $3.03 per share from $11.41 to $8.38, indicating a significant loss of market confidence in the company's future revenue.
- Revenue Guidance Cut: The company revised its fiscal 2027 revenue outlook down from $545-$559 million to $510-$520 million, citing lower-than-expected spending from pharmaceutical clients, which highlights deteriorating visibility in its Network Solutions segment.
- Lawsuit Allegations: A class action lawsuit claims that Phreesia's executives assured investors of consistent revenue visibility throughout the class period, despite weakening commitments from pharmaceutical clients, potentially leading to substantial investor losses.
- Market Reaction: The disclosure revealed Phreesia's heavy reliance on pharmaceutical marketing budgets within its Network Solutions segment, and the market's repricing of shares illustrates the sensitivity to the gap between internal knowledge and external communication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.350
Low
24.00
Averages
29.09
High
35.00
Current: 9.350
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Phreesia Securities Fraud Lawsuit
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating Phreesia, Inc. for allegedly making false and misleading statements to investors between May 8, 2025, and March 30, 2026, causing them to purchase securities at artificially inflated prices.
- Significant Stock Decline: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, resulting in a stock price drop from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market pessimism about the company's future prospects.
- Investor Losses: The company's failure to disclose critical negative information led investors to be unaware of Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in significant financial losses for shareholders.
- Opportunity to Participate in Lawsuit: Eligible investors can apply to be lead plaintiffs in the class action lawsuit by July 13, 2026, and Faruqi & Faruqi encourages anyone with relevant information to contact them to support affected investors.
See More
Phreesia Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, that they must apply to be lead plaintiff by July 13, 2026, or risk losing their right to compensation.
- Fee Arrangement: Investors can participate in the lawsuit without any upfront costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking compensation and encourages broader participation in the class action.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments, which led to investor losses when the truth emerged, indicating a significant trust issue for the company in the market.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its extensive experience and success in handling such cases.
See More
Reminder for Phreesia Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call toll-free at 866-767-3653 for more information, emphasizing the importance of selecting qualified legal counsel to effectively protect their rights.
See More
Phreesia Shareholders Warned: Possible Class Action Lawsuit
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc., encouraging those who purchased shares between May 8, 2025, and March 30, 2026, to contact the firm regarding potential lead plaintiff status for recovery participation.
- False Statements Allegations: The complaint alleges that Phreesia misled investors by providing overly positive statements while concealing significant adverse facts about slowing demand and reduced visibility in its Network Solutions segment, which could have serious implications for investor trust.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, indicating a challenging operational environment ahead.
- Stock Price Decline: Following the announcement, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, marking a 27% decline that underscores the market's negative sentiment towards the company's future performance.
See More
Commvault and Others Under Shareholder Investigation
- Shareholder Investigations Initiated: Grabar Law Office is investigating Commvault Systems, Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors with false and misleading statements regarding its projected ARR growth for fiscal year 2026, leading to significant investor misconceptions about the company's prospects.
- Similar Issues at LKQ: Grabar Law Office is also investigating LKQ Corporation, where executives allegedly failed to disclose critical information about customer losses and declining market share related to the acquisition of Uni-Select, resulting in investor misjudgments about financial health.
- Phreesia's Financial Transparency Questioned: Phreesia, Inc. is under scrutiny for allegedly failing to disclose slowing demand and diminished visibility into revenue streams, which could undermine investor confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit from Shareholders
- Stock Price Plunge: Phreesia's shares dropped 27% after the company revised its fiscal 2027 revenue guidance down from $545 million to a range of $510 million to $520 million, resulting in a loss of $3.03 per share, which severely undermines investor confidence and may impact future financing capabilities.
- Revenue Projection Errors: The lawsuit alleges that Phreesia faced deteriorating visibility into pharmaceutical manufacturers' spending commitments when it issued its fiscal 2027 revenue projections in December 2025, raising doubts about the company's future growth and potentially affecting its market position.
- Declining Pharmaceutical Commitments: Phreesia's Network Solutions segment heavily relied on seasonal spending commitments from pharmaceutical manufacturers, yet management's statements in May and December 2025 were deemed misleading as clients were already reducing spending, which could jeopardize the company's revenue stability.
- Legal Accountability Issues: This lawsuit raises significant questions regarding revenue projection disclosure obligations in the healthcare technology sector, emphasizing that investors are entitled to know the authenticity of spending commitments to make informed investment decisions, potentially leading to improvements in the company's transparency.
See More
Investigation into Phreesia Securities Fraud Lawsuit
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating Phreesia, Inc. for allegedly making false and misleading statements to investors between May 8, 2025, and March 30, 2026, causing them to purchase securities at artificially inflated prices.
- Significant Stock Decline: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, resulting in a stock price drop from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market pessimism about the company's future prospects.
- Investor Losses: The company's failure to disclose critical negative information led investors to be unaware of Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in significant financial losses for shareholders.
- Opportunity to Participate in Lawsuit: Eligible investors can apply to be lead plaintiffs in the class action lawsuit by July 13, 2026, and Faruqi & Faruqi encourages anyone with relevant information to contact them to support affected investors.
See More
Phreesia Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, that they must apply to be lead plaintiff by July 13, 2026, or risk losing their right to compensation.
- Fee Arrangement: Investors can participate in the lawsuit without any upfront costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking compensation and encourages broader participation in the class action.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments, which led to investor losses when the truth emerged, indicating a significant trust issue for the company in the market.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its extensive experience and success in handling such cases.
See More
Reminder for Phreesia Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call toll-free at 866-767-3653 for more information, emphasizing the importance of selecting qualified legal counsel to effectively protect their rights.
See More
Phreesia Shareholders Warned: Possible Class Action Lawsuit
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc., encouraging those who purchased shares between May 8, 2025, and March 30, 2026, to contact the firm regarding potential lead plaintiff status for recovery participation.
- False Statements Allegations: The complaint alleges that Phreesia misled investors by providing overly positive statements while concealing significant adverse facts about slowing demand and reduced visibility in its Network Solutions segment, which could have serious implications for investor trust.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, indicating a challenging operational environment ahead.
- Stock Price Decline: Following the announcement, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, marking a 27% decline that underscores the market's negative sentiment towards the company's future performance.
See More
Commvault and Others Under Shareholder Investigation
- Shareholder Investigations Initiated: Grabar Law Office is investigating Commvault Systems, Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors with false and misleading statements regarding its projected ARR growth for fiscal year 2026, leading to significant investor misconceptions about the company's prospects.
- Similar Issues at LKQ: Grabar Law Office is also investigating LKQ Corporation, where executives allegedly failed to disclose critical information about customer losses and declining market share related to the acquisition of Uni-Select, resulting in investor misjudgments about financial health.
- Phreesia's Financial Transparency Questioned: Phreesia, Inc. is under scrutiny for allegedly failing to disclose slowing demand and diminished visibility into revenue streams, which could undermine investor confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit from Shareholders
- Stock Price Plunge: Phreesia's shares dropped 27% after the company revised its fiscal 2027 revenue guidance down from $545 million to a range of $510 million to $520 million, resulting in a loss of $3.03 per share, which severely undermines investor confidence and may impact future financing capabilities.
- Revenue Projection Errors: The lawsuit alleges that Phreesia faced deteriorating visibility into pharmaceutical manufacturers' spending commitments when it issued its fiscal 2027 revenue projections in December 2025, raising doubts about the company's future growth and potentially affecting its market position.
- Declining Pharmaceutical Commitments: Phreesia's Network Solutions segment heavily relied on seasonal spending commitments from pharmaceutical manufacturers, yet management's statements in May and December 2025 were deemed misleading as clients were already reducing spending, which could jeopardize the company's revenue stability.
- Legal Accountability Issues: This lawsuit raises significant questions regarding revenue projection disclosure obligations in the healthcare technology sector, emphasizing that investors are entitled to know the authenticity of spending commitments to make informed investment decisions, potentially leading to improvements in the company's transparency.
See More
